Pricing Log in Create free account
Friday 6 November 2026 Export JAZZ’s income statement to Excel — free account

Jazz Pharmaceuticals PLC

JAZZ Healthcare Biotechnology

Jazz Pharmaceuticals PLC’s revenue for fiscal 2025 (year ended December 2025) was $4.3 billion, up 4.88% from fiscal 2024.

Revenue
+10.4%
EPS
−280.5%
Free cash flow
−60.4%
Total debt
+3.88%

Quarter to September 2026, against a year earlier

236.74 9.42 +4.14%
Market cap
$14.6B
P/E
62.6×
Fwd P/E
35.9×
Dividend yield
—
F-score
5/9
Altman Z
1.37
Beneish M
−3.03
Dividend safety
n/a
Overview Business Profile Earnings & Analysis
Financials
Income Statement Balance Sheet Cash Flow Metrics & Ratios
Segments Valuation Filings

Jazz Pharmaceuticals PLC (JAZZ) EV/EBITDA

Alert me on EV/EBITDA

As of 5 November 2026, Jazz Pharmaceuticals PLC (JAZZ) trades at a EV/EBITDA of 15.2×. Over the past ten years it has ranged from 6.1× (March 2020) to 74.7× (November 2025); the current reading is higher than 65% of that period. That is above the Biotechnology industry median of 0.7× and above the Healthcare sector median of 8.4×.

EV/EBITDA, daily

Embed this chart

Annual newest first

Period EV/EBITDA Change
FY2025 49.9× 540.51%
FY2024 7.8× (21.71%)
FY2023 10.0× (61.60%)
FY2022 25.9× 43.45%
FY2021 18.1× 29.54%
FY2020 14.0× 39.89%
FY2019 10.0× 6.41%
FY2018 9.4× (26.45%)
FY2017 12.7× 11.08%
FY2016 11.5× (16.75%)

Quarterly newest first

Period EV/EBITDA Change
Sep 2026 15.5× 43.62%
Jun 2026 10.8× (48.76%)
Mar 2026 21.0× (57.93%)
Dec 2025 49.9× (15.51%)
43 more quarters

Against its own ten years

Low 6.1× High 74.7×
Ten-year median 13.8×
Current reading's percentile 65

EV/EBITDA against peers

Company EV/EBITDA
KYMR Kymera Therapeutics, Inc. compare n/m
SMMT Summit Therapeutics PLC compare n/m
BBIO BridgeBio Pharma, Inc. compare n/m
JAZZ Jazz Pharmaceuticals PLC 15.2×
EXEL Exelixis, Inc. compare 15.6×
HALO Halozyme Therapeutics, Inc. compare 22.6×
TECH Bio-Techne Corp compare 32.3×
BMRN BioMarin Pharmaceutical Inc. compare 38.2×
ASND Ascendis Pharma A/S compare 49.5×
Biotechnology industry median 0.7×
Healthcare sector median 8.4×
Market median 10.9×

What EV/EBITDA is

Enterprise Value over EBITDA tells an investor how the market values a whole company, with debt added and cash taken off, against its operating earnings.

((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ EBITDA (TTM)

The full definition of EV/EBITDA →

More on JAZZ